The following table summarizes restructuring, acquisition, and related costs in the accompanying consolidated statements of operations (in thousands):


	Three Months Ended				Six Months Ended
	June 27,		June 28,		June 27,			June 28,
	2025		2024		2025			2024
2025 restructuring	$	6,836	$	—	$	6,836		$	—
2024 restructuring		3,385		2,523		3,975			3,071
2020 restructuring		—		—		(3,595	)		—
Total restructuring charges		10,221		2,523		7,216			3,071
Acquisition and related charges		2,351		20		2,901			1,755
Total restructuring, acquisition, and related costs	$	12,572	$	2,543	$	10,117		$	4,826

The Company initiated the 2025 restructuring program in the second quarter of 2025 in order to streamline operations and align with our long-term goals. The 2025 restructuring program includes measures to regionalize manufacturing operations, expedite the closure of certain sites, streamline management structures, and implement cost-saving strategies in areas anticipated to have a minimal long-term impact on the Company's overall business performance. During both the three and six months ended June 27, 2025, the Company recorded $6.8 million in severance, facility related and other charges in connection with the 2025 restructuring program. As of June 27, 2025, the Company had incurred cumulative costs of $6.8 million related to this restructuring program. The Company anticipates substantially completing the 2025 restructuring program by the end of 2026. Total restructuring charges related to this program are expected to range between $20.0 million to $25.0 million.

The following table summarizes restructuring costs associated with the 2025 restructuring program by reportable segment (in thousands):


	Three Months Ended				Six Months Ended
	June 27,		June 28,		June 27,		June 28,
	2025		2024		2025		2024
Automation Enabling Technologies	$	940	$	—	$	940	$	—
Medical Solutions		4,202		—		4,202		—
Unallocated		1,694		—		1,694		—
Total	$	6,836	$	—	$	6,836	$	—

As a result of the Company’s acquisitions and ongoing integration activities, the Company initiated the 2024 restructuring program in the first quarter of 2024 in order to reduce operating complexity. During the three and six months ended June 27, 2025, the Company recorded $3.4 million and $4.0 million, respectively, in severance, facility related and other charges in connection with the 2024 restructuring program. As of June 27, 2025, the Company had incurred cumulative costs of $14.5 million related to this restructuring program. The Company anticipates substantially completing the 2024 restructuring program by the end of 2025 and expects to incur additional restructuring charges of $1.5 million to $2.5 million related to the 2024 restructuring program.

The following table summarizes restructuring costs associated with the 2024 restructuring program by reportable segment (in thousands):


	Three Months Ended				Six Months Ended
	June 27,		June 28,		June 27,		June 28,
	2025		2024		2025		2024
Automation Enabling Technologies	$	445	$	1,810	$	931	$	2,089
Medical Solutions		2,930		360		3,012		566
Unallocated		10		353		32		416
Total	$	3,385	$	2,523	$	3,975	$	3,071

As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2020 restructuring program in the third quarter of 2020. This program was focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program was focused on cost reduction actions to improve gross margins for the overall company. As of June 27, 2025, the Company had incurred cumulative costs of $13.1 million related to the 2020 restructuring program. The 2020 restructuring program activities were completed in the fourth quarter of 2023. In January 2025, the Company sold a facility from the 2020 restructuring program and recorded a $3.6 million gain in the Company’s Automation Enabling Technologies segment.

The following table summarizes the accrual activities, by component, related to the Company’s restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):


	Total			Employee Related			Facility Related			Facility Sale			Other
Balance at December 31, 2024	$	6,751		$	5,690		$	1,061		$	—		$	—
Restructuring charges		7,216			9,191			1,503			(4,325	)		847
Cash payments		1,849			(2,573	)		(335	)		5,537			(780	)
Non-cash write-offs and other adjustments		(1,839	)		719			(1,346	)		(1,212	)		—
Balance at June 27, 2025	$	13,977		$	13,027		$	883		$	—		$	67

Acquisition costs in connection with business combinations, including advisor, legal, valuation, and other professional or consulting fees, totaled $2.4 million and $2.9 million for the three and six months ended June 27, 2025, and less than $0.1 million and $1.8 million for the three and six months ended June 28, 2024. The majority of acquisition and related costs for the three and six months ended June 27, 2025 and the three and six months ended June 28, 2024 were included in unallocated costs.